Structuralformula (Ab3f3920 2554 4b1f B965 9b41035ab21b 01)
Capecitabine
Product Images NDC 83774-101
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Capecitabine (NDC 83774-101). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Pilnova Pharma Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 Kaplan-meier Estimates Of Disease-free Survival (all Randomized Population)a (Ab3f3920 2554 4b1f B965 9b41035ab21b 02)
This text seems to show the effectiveness of two treatment groups (5FU + LEUCOVORIN and CAPECITABINE) over a period of 96 months. The data appears to include the number of events occurring at each time point for both treatment groups. It could be related to a clinical trial or study comparing the outcomes of these treatment regimens.*
Figure 2 Kaplan-meier Estimates Of Overall Survival (all Randomized Population) (Ab3f3920 2554 4b1f B965 9b41035ab21b 03)
.. (Ab3f3920 2554 4b1f B965 9b41035ab21b 04)
This is an estimation of probability related to a medical treatment involving 5-FU, Leucovorin, and Capecitabine for a certain duration. The graph shows the probability values over specific time intervals in days. The treatment seems to have varying levels of probabilities at different time points.*
Figure 4 Kaplan-meier Estimates For Time To Disease Progression Capecitabine And Docetaxel Vs Docetaxel (Ab3f3920 2554 4b1f B965 9b41035ab21b 05)
Figure 5 Kaplan-meier Estimates Of Survival Capecitabine And Docetaxel Vs Docetaxel (Ab3f3920 2554 4b1f B965 9b41035ab21b 06)
This text includes information related to the estimated probability of different treatment combinations involving Docetaxel, Capecitabine, and Widocetaxel administered over specific time intervals. The data seems to represent a chart with values ranging from 0.0 to 1.0 against time in days. It could be part of a medical or scientific analysis regarding the effectiveness or outcomes of these treatments over a certain period.*
150mg (Ab3f3920 2554 4b1f B965 9b41035ab21b 07)
The text provides information on a medication called capecitabine, which is presented in the form of film-coated tablets with 150 mg strength. It includes details on dosage recommendations, administration instructions, storage conditions, manufacturer details, and batch coding information. The medication is intended to be swallowed whole and not to be crushed or cut. It is important to dispense in tight containers and store at specific temperatures. Manufacturer details include Alembic Pharmaceuticals Limited and Pilnova Pharma Inc. This information is helpful for understanding the proper use and handling of capecitabine tablets.*
500mg (Ab3f3920 2554 4b1f B965 9b41035ab21b 08)
This text appears to be a medication label for Capecitabine tablets. It mentions the dosage and storage instructions for the tablets. The tablets contain 500 mg of capecitabine, USP, and should be swallowed whole without crushing or cutting them. The medication should be dispensed in tight containers and stored within certain temperature ranges. The label also provides batch coding and barcode information for reference.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
